PPIDT00242

Drug Information
NameBelimumab
SequenceSSELTQDPAVSVALGQTVRVTCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCSSRDSSGNHWVFGGGTELTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
DrugBank_IDDB08879
Typebiotech
IndicationIn the US, belimumab is indicated to treat active systemic lupus erythematosus (SLE) and active lupus nephritis in patients aged five years and older who are receiving standard therapy.[L42630] In Europe, belimumab is also used to treat SLE and lupus nephritis but only in adults.[L42705] The efficacy of belimumab has not been evaluated in patients with severe active central nervous system lupus. Use of belimumab is not recommended in this situation.[L42630]

Dosage Forms
Form Route Strength
Injection, powder, for solution Intravenous
120 MG
Injection, powder, for solution Intravenous
400 MG
Injection, powder, lyophilized, for solution Intravenous
120 mg/1.5mL
Injection, powder, lyophilized, for solution Intravenous
400 mg/5mL
Injection, solution Parenteral; Subcutaneous
200 MG
Injection, solution Subcutaneous
200 mg
Powder, for solution Intravenous
120 mg / vial
Powder, for solution Intravenous
400 mg / vial
Solution Subcutaneous
200 mg / 1 mL
Solution Subcutaneous
200 mg/1mL
Injection, solution Intravenous
120 mg
Injection, powder, lyophilized, for solution Intravenous
12000000 mg
Solution Subcutaneous
20000000 mg
Injection Intravenous
400 mg
Injection, powder, lyophilized, for solution Intracavernous
400 mg
Injection, powder, lyophilized, for solution Intravenous
40000000 mg
Injection, powder, lyophilized, for solution Intravenous
120 mg
Injection, powder, lyophilized, for solution Intravenous
400 mg
Suspension Subcutaneous
20000000 mg
Solution Intravenous
120.000 mg
Solution Subcutaneous
200 mg
Target Information
Role Uniprot_ID Gene_Name Entity_Name Organism Actions Internal link
target Q9Y275 TNFSF13B Tumor necrosis factor ligand superfamily member 13B Homo sapiens antibody Link